ClinicalTrials.gg
CompletedNCT01524939Updated Sep 20, 2012

Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease

A Phase 4 interventional study of immunoglobulin G in Kawasaki Disease, sponsored by Green Cross Corporation. Completed at 7 sites in Korea, Republic of. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2012-09-20.

Sponsored by Green Cross Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
6 Months to 5 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, efficacy and of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with kawasaki diseases.

Read the detailed description

This clinical trial was designed as a multicenter, single-arm, and open-label clinical trial.

Evaluate the incidence of coronary artery lesions in the 7th week of IVIG-SN administration, compared to the incidence of coronary artery lesions among untreated Kawasaki patients, to prove the superior efficacy of IVIG-SN.

02

Conditions studied

  • Kawasaki Disease
03

In context

Mucocutaneous Lymph Node Syndrome

62 studies on the registry are indexed under Mucocutaneous Lymph Node Syndrome; 17 are open to participants now.

This study's enrollment of 45 is close to the median of 45 across 33 interventional studies indexed under Mucocutaneous Lymph Node Syndrome.

Browse Mucocutaneous Lymph Node Syndrome studies →

Lead sponsor

Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pediatric patients aged 6 months - 5 years
  2. Case definition for complete KD: Fever (≥ 38.5°C) for ≥ 5 days (but less than 10 days), 4/5 standard clinical criteria
  3. Case definition for incomplete KD: Fever ≥ 5 days(but less than 10 days) and 3 clinical criteria plus coronary artery lesion on echocardiogram.
  4. Subjects whose parents or legally acceptable representative (LAR) gave voluntary written consent to participate in this clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Those whose blood test results show abnormalities of significance as follows : count \< 100,000/mm3, WBC count \<3,000 cells/mm3,Those whose hemogloblin, hematocrit or red blood cell count exceed 30% of the or are 30% below the lower limit of the normal range.
  2. Those who have been administered other clinical product in the last 30 days after this clinical trial commenced
  3. Those who have been administered TNF alpha or within 48 hours after being administered the test product
  4. Those who plan to be inoculated with during the clincial trial period
  5. Those considered difficult to participate in clinical trial due to serious chronic diseases(e.g., cardiovascular diseases except controllable hypertension, diseases of the respiratory system concurrent with respiratory failure, metabolic disease, kidney dysfunction, hemoglobinopathy, etc.)
  6. Those who have been administered an or immune modifying drug in the last 3 months before the innoculation with the test product
  7. Those who are -positive or have immune dysfunctions including immunodeficiency
  8. Those who have previously exhibited or shock to IVIG agents
  9. Patients with underlying liver disease or liver dysfunction with known etiology.
  10. Patients with kidney dysfunction, whose Creatinine level is found to be over 2 times higher than the upper limit of the normal ranges in a screening test
  11. Those who have -- or previously had -- a malignant tumor
  12. Those who have previously been diagnosed with IgA deficiency
  13. Those found unsuitable for undergoing the tests
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Investigational product

    Drug: immunoglobulin G

Interventions

  • Intravenously administer a single dose of the product (2g/kg) for at least 12 hours

06

What researchers measure

Primary outcomes

  1. Incidence of coronary artery lesions

    Incidence of coronary artery lesions in the 7 weeks after IVIG-SN infusion

    Time frame: 7 weeks

Secondary outcomes

  1. Incidence of coronary artery lesions

    Incidence of coronary artery lesions in the 2nd week after IVIG-SN infusion

    Time frame: 2weeks

  2. Total fever duration

    Total fever duration after IVIG-SN infusion

    Time frame: baseline

  3. variation of ESR, CRP, NT-proBNP,CK-MB

    Evaluation in variation of ESR, CRP, NT-proBNP or BNP, and CK-MB

    Time frame: baseline

07

Study locations

7 sites
  • Wonju christian Hospital
    Wonju, Kang-won 220-701, Korea, Republic of
  • Gachon University Gil Hospital
    Incheon, Korea, Republic of
  • Asan Medical center
    Seoul, Korea, Republic of
  • Kyung Hee university at Gangdong
    Seoul, Korea, Republic of
  • Kyung Hee university medical center
    Seoul, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Seoul ST. Mary's Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2012
First posted
Feb 2, 2012
Start
Jan 2012
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Last update
Sep 20, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01524939
Responsible party
Sponsor
First posted
Feb 2, 2012
Start date
Jan 2012
Primary completion
Sep 2012
Completion
Sep 2012
Last update
Sep 20, 2012

Study contacts

June Huh, MD,Ph.D
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulin G

Start the discussion